The Swiss Cancer Cascade Genetic Screening Consortium is a Swiss-based collaboration of stakeholders from basic research, the healthcare system, and social sciences. The goal of the consortium is to provide information and expert support to families with pathogenic mutations connected to breast/ovarian cancer and to Lynch syndrome.
Swiss men and women with specific genetic mutations have higher risk for breast, ovarian, colorectal, endometrial and other cancers compared to other persons without such mutations. These pathogenic mutations are passed down from one generation to the next and can affect many family members. It is common that family members need expert coordination of care and support to cope with cancer.
The CASCADE study will take place in three linguistic regions of Switzerland.
The goals are to:
- examine hereditary cancer risk connected to pathogenic mutations
- assess the quality of life, medical, and psychosocial needs of mutation carriers and their blood relatives, and how these needs change over time
- facilitate coordination of cancer surveillance
- provide expert information about use of cancer genetic services
- promote interventions designed to help family members cope with cancer and communicate with each other